Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 8/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 5/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753313 | 1.00 | MAPK8 (0.44) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL2753316 | 1.00 | MAPK8 (0.44) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL2751905 | 0.87 | MAPK8 (0.44) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL2751908 | 0.87 | MAPK8 (0.44) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL4406150 | 0.87 | MAPK8 (0.44) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL2753209 | 0.87 | MAPK8 (0.58) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL2753208 | 0.87 | MAPK8 (0.58) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL4401825 | 0.87 | MAPK8 (0.58) | MAPK8MAPK9MAPK10ACVR1IRAK4 | |
| SCHEMBL8177630 | 0.86 | BRD4 (0.39) | BRD4 | |
| SCHEMBL4401919 | 0.84 | MAPK8 (0.60) | MAPK8MAPK9MAPK10ACVR1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | MAPK8 26/4885MAPK9 20/4885MAPK10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.